FdaApplication
NDA 021880
Identifiers
- fda_app_no: NDA021880
Properties
| Property | Value |
|---|---|
| applicant_name | BRISTOL MYERS SQUIBB |
| application_type | NDA |
| approval_date | 2005-12-27 |
Revenue by product
REVLIMID
| Period | Revenue |
|---|---|
| Q2 2026 | $425.0M |
| Q1 2026 | $349.0M |
| Q4 2025 | $602.0M |
| Q3 2025 | $575.0M |
| Q2 2025 | $838.0M |
| Q1 2025 | $936.0M |
| Q4 2024 | $1.3B |
| Q3 2024 | $1.4B |
| Q2 2024 | $1.4B |
| Q1 2024 | $1.7B |
| Q4 2023 | $1.4B |
| Q3 2023 | $1.4B |
| Q2 2023 | $1.5B |
| Q1 2023 | $1.8B |
| Q4 2022 | $2.3B |
| Q3 2022 | $2.4B |
| Q2 2022 | $2.5B |
| Q1 2022 | $2.8B |
| Q4 2021 | $3.3B |
| Q3 2021 | $3.3B |
| Q2 2021 | $3.2B |
| Q1 2021 | $2.9B |
| Q4 2020 | $3.3B |
| Q3 2020 | $3.0B |
| Q2 2020 | $2.9B |
| Q1 2020 | $2.9B |
| Q4 2019 | $1.3B |
| Q3 2019 | $0.0M |
| Q2 2019 | $0.0M |
| Q1 2019 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (6)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| REVLIMID | LENALIDOMIDE | 10MG | CAPSULE;ORAL |
| REVLIMID | LENALIDOMIDE | 20MG | CAPSULE;ORAL |
| REVLIMID | LENALIDOMIDE | 2.5MG | CAPSULE;ORAL |
| REVLIMID | LENALIDOMIDE | 5MG | CAPSULE;ORAL |
| REVLIMID | LENALIDOMIDE | 15MG | CAPSULE;ORAL |
| REVLIMID | LENALIDOMIDE | 25MG | CAPSULE;ORAL |
6 products